Nijland, Marcel
University Medical Center Groningen · University of Groningen
3 papers on CoChatORCID 0000-0002-2740-2873
Most cited papers
- Verified
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.
Falchi, L., Nijland, M., Huang, H., Linton, K. M., Seymour, J. F., Tao, R., Kwiatek, M., Costa, A., Vassilakopoulos, T. P., Greil, R., et al. (2026) · The Lancet
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research
Cited by 41
- Verified
Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma
Falchi, L., Sureda, A., Leppä, S., Vermaat, J. S. P., Nijland, M., Christensen, J. H., de Vos, S., Holte, H., Merryman, R. W., Lugtenburg, P. J., et al. (2025) · Blood
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research
Cited by 15
- Verified
Ibrutinib tablet splitting as a practical strategy for dose reduction in the management of drug–drug interactions
Jager, L., Koopmans, P., Westra, N., Nijland, M., Hooge, M. L.-D., & Munnink, T. O. (2026) · Journal of Oncology Pharmacy Practice
Chronic Lymphocytic Leukemia ResearchPharmacogenetics and Drug Metabolism
Cited by 0
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free